6.
Kang H, Auzenbergs M, Clapham H, Maure C, Kim J, Salje H
. Chikungunya seroprevalence, force of infection, and prevalence of chronic disability after infection in endemic and epidemic settings: a systematic review, meta-analysis, and modelling study. Lancet Infect Dis. 2024; 24(5):488-503.
DOI: 10.1016/S1473-3099(23)00810-1.
View
7.
Jain J, Nayak K, Tanwar N, Gaind R, Gupta B, Shastri J
. Clinical, Serological, and Virological Analysis of 572 Chikungunya Patients From 2010 to 2013 in India. Clin Infect Dis. 2017; 65(1):133-140.
DOI: 10.1093/cid/cix283.
View
8.
Quiroz J, Malonis R, Thackray L, Cohen C, Pallesen J, Jangra R
. Human monoclonal antibodies against chikungunya virus target multiple distinct epitopes in the E1 and E2 glycoproteins. PLoS Pathog. 2019; 15(11):e1008061.
PMC: 6837291.
DOI: 10.1371/journal.ppat.1008061.
View
9.
Nayak K, Jain V, Kaur M, Khan N, Gottimukkala K, Aggarwal C
. Antibody response patterns in chikungunya febrile phase predict protection versus progression to chronic arthritis. JCI Insight. 2020; 5(7).
PMC: 7205261.
DOI: 10.1172/jci.insight.130509.
View
10.
Basore K, Kim A, Nelson C, Zhang R, Smith B, Uranga C
. Cryo-EM Structure of Chikungunya Virus in Complex with the Mxra8 Receptor. Cell. 2019; 177(7):1725-1737.e16.
PMC: 7227486.
DOI: 10.1016/j.cell.2019.04.006.
View
11.
Zhang R, Hryc C, Cong Y, Liu X, Jakana J, Gorchakov R
. 4.4 Å cryo-EM structure of an enveloped alphavirus Venezuelan equine encephalitis virus. EMBO J. 2011; 30(18):3854-63.
PMC: 3173789.
DOI: 10.1038/emboj.2011.261.
View
12.
Couderc T, Khandoudi N, Grandadam M, Visse C, Gangneux N, Bagot S
. Prophylaxis and therapy for Chikungunya virus infection. J Infect Dis. 2009; 200(4):516-23.
PMC: 7109959.
DOI: 10.1086/600381.
View
13.
De Caluwe L, Heyndrickx L, Coppens S, Vereecken K, Quinones-Mateu M, Merits A
. Chikungunya Virus' High Genomic Plasticity Enables Rapid Adaptation to Restrictive A549 Cells. Viruses. 2022; 14(2).
PMC: 8879786.
DOI: 10.3390/v14020282.
View
14.
Fox J, Huang L, Tahan S, Powell L, Crowe Jr J, Wang D
. A cross-reactive antibody protects against Ross River virus musculoskeletal disease despite rapid neutralization escape in mice. PLoS Pathog. 2020; 16(8):e1008743.
PMC: 7433899.
DOI: 10.1371/journal.ppat.1008743.
View
15.
Sun S, Xiang Y, Akahata W, Holdaway H, Pal P, Zhang X
. Structural analyses at pseudo atomic resolution of Chikungunya virus and antibodies show mechanisms of neutralization. Elife. 2013; 2:e00435.
PMC: 3614025.
DOI: 10.7554/eLife.00435.
View
16.
Morrison T, Oko L, Montgomery S, Whitmore A, Lotstein A, Gunn B
. A mouse model of chikungunya virus-induced musculoskeletal inflammatory disease: evidence of arthritis, tenosynovitis, myositis, and persistence. Am J Pathol. 2011; 178(1):32-40.
PMC: 3069999.
DOI: 10.1016/j.ajpath.2010.11.018.
View
17.
Couturier E, Guillemin F, Mura M, Leon L, Virion J, Letort M
. Impaired quality of life after chikungunya virus infection: a 2-year follow-up study. Rheumatology (Oxford). 2012; 51(7):1315-22.
DOI: 10.1093/rheumatology/kes015.
View
18.
Cereghino C, Roesch F, Carrau L, Hardy A, Ribeiro-Filho H, Henrion-Lacritick A
. The E2 glycoprotein holds key residues for Mayaro virus adaptation to the urban Aedes aegypti mosquito. PLoS Pathog. 2023; 19(4):e1010491.
PMC: 10109513.
DOI: 10.1371/journal.ppat.1010491.
View
19.
Weger-Lucarelli J, Aliota M, Kamlangdee A, Osorio J
. Identifying the Role of E2 Domains on Alphavirus Neutralization and Protective Immune Responses. PLoS Negl Trop Dis. 2015; 9(10):e0004163.
PMC: 4608762.
DOI: 10.1371/journal.pntd.0004163.
View
20.
McCarthy M, Davenport B, Reynoso G, Lucas E, May N, Elmore S
. Chikungunya virus impairs draining lymph node function by inhibiting HEV-mediated lymphocyte recruitment. JCI Insight. 2018; 3(13).
PMC: 6124534.
DOI: 10.1172/jci.insight.121100.
View